Sorrento Announces IND Filing for COVI-DROPS, an Intranasal Formulation of a High Potency Neutralizing Antibody Against SARS-CoV-2
November 11, 2020 09:00 ET
|
Sorrento Therapeutics, Inc.
IND filing today for STI-2099 (COVI-DROPS™) for a phase 1 safety and pharmacokinetic study in healthy volunteers and outpatients with mild COVID-19 disease with or without a simultaneous intravenous...
Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Therapeutics’ Large Phase 2 Clinical Trial of Abivertinib in Mild, Moderate and Severe COVID-19 Patients
October 14, 2020 11:57 ET
|
Sorrento Therapeutics, Inc.
Phase 2 clinical trials of Abivertinib now cleared to proceed in both Brazil and the U.S.Studies are complementary and address both dose duration and disease stageRapid enrollment expected for both...
Sorrento COVID-19 R&D October 13, 2020 Pipeline Call Details Released
October 09, 2020 19:46 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today released details about its upcoming COVID-19 Pipeline Update call and webcast on October...
Scilex Holding Company, a Subsidiary of Sorrento Therapeutics, Announces Continuous Sales Growth in ZTlido® and Expects to Complete Enrollment on its SP-102 (SEMDEXA™) Phase 3 Pivotal Trial Program in 2020
October 07, 2020 06:00 ET
|
Sorrento Therapeutics, Inc.
Preliminary Q3 2020 net sales of ZTlido® of approximately $7.2 million, quarter-over-quarter growth of 26% compared to $5.7MM in Q2-2020 despite the continued impact of COVID-19 pandemic.The Phase 3...
Sorrento to Host a R&D Day to Showcase COVID-19 Product Pipeline
October 04, 2020 18:39 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Oct. 04, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced it will host a R&D Day conference call and simultaneous webcast on October...
Sorrento Therapeutics and ViralClear Enter Into Agreement to Explore Combination Antibody Plus Antiviral Therapy Against COVID-19
September 30, 2020 09:00 ET
|
Sorrento Therapeutics, Inc.
Sorrento to initiate testing with a selection of its agents in combination with ViralClear’s anti-viral compound for possible synergistic anti-viral effect against SARS-CoV-2 in the preclinical model...
Sorrento Releases Preclinical Data for STI-1499 (COVI-Guard™) and STI-2020 (COVI-AMG™), Potent Neutralizing Antibodies Against SARS-CoV-2
September 28, 2020 23:59 ET
|
Sorrento Therapeutics, Inc.
In preclinical studies, both STI-1499 and STI-2020 demonstrated potent neutralizing activity against SARS-CoV-2 virus isolates, including the emerging Spike D614G variant virus.Both STI-1499 and...
Sorrento Therapeutics Releases Positive Results of Phase 1B Trial of Resiniferatoxin (RTX) Epidural in Cancer Patients with Reported Intractable Pain
September 22, 2020 14:30 ET
|
Sorrento Therapeutics, Inc.
Seventeen subjects with advanced cancer pain received epidural RTX (0.4 to 25 mcg).No dose limiting toxicities were reported.A majority of patients reported meaningful pain reduction of 30% or more...
Sorrento Therapeutics Presents Interim Positive Results of Phase 1b Resiniferatoxin (RTX) in Cancer Pain Trial
February 27, 2020 15:30 ET
|
Sorrento Therapeutics, Inc.
Fourteen subjects with advanced cancer pain received epidural RTX (04 to 15 ug)Most common treatment-related adverse event was transient post-procedure related painThree subjects at the higher doses...
Sorrento CEO to Present at Upcoming Investor Conferences
November 12, 2019 07:05 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in upcoming investor...